These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11368364)

  • 1. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo.
    Goł b J; Zagozdzon R; Kamiński R; Kozar K; Gryska K; Izycki D; Mackiewicz A; Stokłosa T; Giermasz A; Lasek W; Jakóbisiak M
    Leukemia; 2001 Apr; 15(4):613-20. PubMed ID: 11368364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
    Golab J; Zagozdzon R; Kozar K; Kaminski R; Giermasz A; Stoklosa T; Lasek W; Jakobisiak M
    Oncol Rep; 2000; 7(1):177-81. PubMed ID: 10601614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin.
    Zagozdzon R; Gołab J; Stokłosa T; Giermasz A; Nowicka D; Feleszko W; Lasek W; Jakóbisiak M
    Int J Cancer; 1998 Aug; 77(5):720-7. PubMed ID: 9688305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
    Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
    Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production.
    Zagozdzon R; Giermasz A; Gołab J; Stokłosa T; Jalili A; Jakóbisiak M
    Cancer Lett; 1999 Dec; 147(1-2):67-75. PubMed ID: 10660091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of Actinobacillus suis cells in combination with 5-fluorouracil on mice bearing murine L1210 leukemia cells.
    Watanabe T; Itoh S
    Cancer Immunol Immunother; 1997 Jun; 44(4):216-20. PubMed ID: 9222280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
    Fujimoto S
    Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
    Lasek W; Sora M; Wańkowicz A; Jakóbisiak M
    Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.
    Umeda Y; Sakamoto A; Nakamura J; Ishitsuka H; Yagi Y
    Cancer Immunol Immunother; 1983; 15(2):78-83. PubMed ID: 6553515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.
    Wang XS; Sheng Z; Ruan YB; Guang Y; Yang ML
    World J Gastroenterol; 2005 Feb; 11(8):1220-4. PubMed ID: 15754409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging.
    Mao XY; Higashigawa M; M'Soka T; Shimono Y; Nagata T; Inamochi H; Cao DC; Hori H; Kawasaki H; Sakurai M
    Cancer Invest; 1999; 17(7):486-93. PubMed ID: 10518193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma.
    Biber JL; Jabbour S; Parihar R; Dierksheide J; Hu Y; Baumann H; Bouchard P; Caligiuri MA; Carson W
    Cell Immunol; 2002; 216(1-2):31-42. PubMed ID: 12381348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity.
    Kishida K; Masuho Y; Saito M; Hara T; Fuji H
    Cancer Immunol Immunother; 1983; 16(2):93-7. PubMed ID: 6559105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration.
    Orange JS; Wang B; Terhorst C; Biron CA
    J Exp Med; 1995 Oct; 182(4):1045-56. PubMed ID: 7561678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antileukemic effect in combination of 5-fluorouracil and OK-432.
    Koshimura S; Ryoyama K
    Cancer Treat Rep; 1977; 61(1):17-27. PubMed ID: 324619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination therapy of α-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice.
    Aketa H; Tatsumi T; Kohga K; Tsunematsu H; Aono S; Shimizu S; Kodama T; Nawa T; Shigekawa M; Hikita H; Sakamori R; Hosui A; Miyagi T; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    Int J Cancer; 2013 Sep; 133(5):1126-34. PubMed ID: 23420533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.